Hoba Therapeutics

Hoba Therapeutics is a private, preclinical-stage biotech leveraging a novel platform of endogenous neurotrophic proteins, meteorin and cometin, to develop restorative treatments for sensory neuron disorders. Its lead program, HB-086, targets neuropathic pain (CIPN and trigeminal neuralgia) and is in late preclinical development, while HB-097 targets ototoxic hearing loss in preclinical stages. The company is backed by notable investors like Novo Holdings and Eir Ventures, having recently raised a €23 million Series A round in late 2023 to advance its pipeline.

Platform based on endogenous human neurotrophic proteins, meteorin and cometin, which support the development, growth, survival, and maintenance of nerve cells and glial cells in sensory pathways.

The neuropathic pain space is crowded with many mechanisms under investigation, including other neurotrophic factors, ion channel modulators, and non-opioid analgesics. The hearing loss restoration field is less crowded therapeutically but includes gene therapy and regenerative medicine approaches from both biotech and large pharma. Hoba's differentiation lies in its specific endogenous protein platform.